We are live on ! Find out more
SPRO icon

Spero Therapeutics
SPRO

60 hedge funds and large institutions have $93.2M invested in Spero Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 15

0.19% more ownership

Funds ownership: 56.54% → 56.73% (+0.19%)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

2% less funds holding

Funds holding: 61 → 60 (-1)

10% less capital invested

Capital invested by funds: $104M → $93.2M (-$10.8M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
60
Holders Change
-1
Holders Change %
-1.64%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
7
Increased
31
Reduced
15
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Aquilo Capital Management
California
+$5.85M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.17M
3
BlackRock
BlackRock
New York
+$1.11M
4
RSCM
Rock Springs Capital Management
Maryland
+$705K
5
AG
Artal Group
Luxembourg
+$670K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$2.49M
2
O
OrbiMed
New York
-$1.27M
3
AIC
AWM Investment Company
New York
-$691K
4
OAM
Oxford Asset Management
United Kingdom
-$566K
5
JP Morgan Chase
JP Morgan Chase
New York
-$486K
Name Holding Trade Value Shares
Change 		Change in
Stake
GWM
51
Geneos Wealth Management
Colorado
$28K +$31.8K +3,611 New
Legal & General Group
52
Legal & General Group
United Kingdom
$13K -$4.01K -455 -21%
MAM
53
Meeder Asset Management
Ohio
$13K +$9.47K +1,074 +201%
Morgan Stanley
54
Morgan Stanley
New York
$11K -$134K -15,158 -92%
PCM
55
Prelude Capital Management
New York
$6K -$1.76K -200 -22%
RE
56
RBC Europe
United Kingdom
$5.56K +$793 +90 +15%
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$5K -$5.45K -618 -52%
AIP
58
Ameritas Investment Partners
Nebraska
$4K – – –
US Bancorp
59
US Bancorp
Minnesota
$4K – – –
GI
60
Gradient Investments
Minnesota
$2K +$229 +26 +15%
O
61
OrbiMed
New York
– -$1.27M -131,653 Closed
OAM
62
Oxford Asset Management
United Kingdom
– -$566K -58,868 Closed
PNC Financial Services Group
63
PNC Financial Services Group
Pennsylvania
– -$308K -32,000 Closed
Two Sigma Investments
64
Two Sigma Investments
New York
– -$181K -18,828 Closed
State of Wisconsin Investment Board
65
State of Wisconsin Investment Board
Wisconsin
– -$159K -16,500 Closed
PPA
66
Parametric Portfolio Associates
Washington
– -$97K -10,053 Closed
Bank of Montreal
67
Bank of Montreal
Ontario, Canada
– -$13K -1,357 Closed
1 2
3

SPRO Hedge Fund Activity: Q1 2020 in Review

60 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2020, worth a combined $93.2M — down 10% from $104M a quarter earlier.

Fund positioning in SPRO was balanced in Q1 2020: 7 funds opened new positions, 7 closed out, 31 added to existing stakes and 15 trimmed.

The largest buyer was Aquilo Capital Management, adding an estimated $5.85M. The largest seller was BVF Inc, cutting an estimated $2.49M.

  • 60 institutional investors held Spero Therapeutics (SPRO) as of Q1 2020, down from 61 in Q4 2019.
  • Funds reported $93.2M of Spero Therapeutics stock for Q1 2020, down 10% quarter-over-quarter.
  • 7 funds opened new Spero Therapeutics positions in Q1 2020 and 7 closed out, a net change of 0 holders.
  • The largest Spero Therapeutics buyer in Q1 2020 was Aquilo Capital Management, an estimated $5.85M added.
  • The largest Spero Therapeutics seller in Q1 2020 was BVF Inc, an estimated $2.49M sold.

Based on aggregated 13F filings for Q1 2020.